Literature DB >> 16176184

Analysis of hepatic gene transcription in mice expressing insulin-insensitive GSK3.

Christopher Lipina1, Xu Huang, David Finlay, Edward J McManus, Dario R Alessi, Calum Sutherland.   

Abstract

GSK3 (glycogen synthase kinase-3) regulation is proposed to play a key role in the hormonal control of many cellular processes. Inhibition of GSK3 in animal models of diabetes leads to normalization of blood glucose levels, while high GSK3 activity has been reported in Type II diabetes. Insulin inhibits GSK3 by promoting phosphorylation of a serine residue (Ser-21 in GSK3alpha, Ser-9 in GSK3beta), thereby relieving GSK3 inhibition of glycogen synthesis in muscle. GSK3 inhibition in liver reduces expression of the gluconeogenic genes PEPCK (phosphoenolpyruvate carboxykinase), G6Pase (glucose-6-phosphatase), as well as IGFBP1 (insulin-like growth factor binding protein-1). Overexpression of GSK3 in cells antagonizes insulin regulation of these genes. In the present study we demonstrate that regulation of these three genes by feeding is normal in mice that express insulin-insensitive GSK3. Therefore inactivation of GSK3 is not a prerequisite for insulin repression of these genes, despite the previous finding that GSK3 activity is absolutely required for maintaining their expression. Interestingly, insulin injection of wild-type mice, which activates PKB (protein kinase B) and inhibits GSK3 to a greater degree than feeding (50% versus 25%), does not repress these genes. We suggest for the first time that although pharmacological inhibition of GSK3 reduces hepatic glucose production even in insulin-resistant states, feeding can repress the gluconeogenic genes without inhibiting GSK3.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16176184      PMCID: PMC1316304          DOI: 10.1042/BJ20051046

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  39 in total

1.  Surgical removal of visceral fat reverses hepatic insulin resistance.

Authors:  N Barzilai; L She; B Q Liu; P Vuguin; P Cohen; J Wang; L Rossetti
Journal:  Diabetes       Date:  1999-01       Impact factor: 9.461

2.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

3.  Roles of the forkhead in rhabdomyosarcoma (FKHR) phosphorylation sites in regulating 14-3-3 binding, transactivation and nuclear targetting.

Authors:  G Rena; A R Prescott; S Guo; P Cohen; T G Unterman
Journal:  Biochem J       Date:  2001-03-15       Impact factor: 3.857

Review 4.  PEPCK gene as model of inhibitory effects of insulin on gene transcription.

Authors:  R M O'Brien; D K Granner
Journal:  Diabetes Care       Date:  1990-03       Impact factor: 19.112

5.  Insulin stimulates phosphorylation of the forkhead transcription factor FKHR on serine 253 through a Wortmannin-sensitive pathway.

Authors:  J Nakae; B C Park; D Accili
Journal:  J Biol Chem       Date:  1999-06-04       Impact factor: 5.157

6.  Inhibition of GSK-3 selectively reduces glucose-6-phosphatase and phosphatase and phosphoenolypyruvate carboxykinase gene expression.

Authors:  P A Lochhead; M Coghlan; S Q Rice; C Sutherland
Journal:  Diabetes       Date:  2001-05       Impact factor: 9.461

7.  Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes.

Authors:  S E Nikoulina; T P Ciaraldi; S Mudaliar; P Mohideen; L Carter; R R Henry
Journal:  Diabetes       Date:  2000-02       Impact factor: 9.461

8.  Regulation of SREBP-1 expression and transcriptional action on HKII and FAS genes during fasting and refeeding in rat tissues.

Authors:  Yvan Gosmain; Nicolas Dif; Vanessa Berbe; Emmanuelle Loizon; Jennifer Rieusset; Hubert Vidal; Etienne Lefai
Journal:  J Lipid Res       Date:  2005-01-01       Impact factor: 5.922

9.  Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling.

Authors:  C Sutherland; I A Leighton; P Cohen
Journal:  Biochem J       Date:  1993-11-15       Impact factor: 3.857

10.  A secondary phosphorylation of CREB341 at Ser129 is required for the cAMP-mediated control of gene expression. A role for glycogen synthase kinase-3 in the control of gene expression.

Authors:  C J Fiol; J S Williams; C H Chou; Q M Wang; P J Roach; O M Andrisani
Journal:  J Biol Chem       Date:  1994-12-23       Impact factor: 5.157

View more
  12 in total

Review 1.  Role of glycogen synthase kinase-3beta in cardioprotection.

Authors:  Magdalena Juhaszova; Dmitry B Zorov; Yael Yaniv; H Bradley Nuss; Su Wang; Steven J Sollott
Journal:  Circ Res       Date:  2009-06-05       Impact factor: 17.367

Review 2.  Targeting glycogen synthase kinase-3 (GSK-3) in the treatment of Type 2 diabetes.

Authors:  Katrina MacAulay; James R Woodgett
Journal:  Expert Opin Ther Targets       Date:  2008-10       Impact factor: 6.902

3.  AMP-activated protein kinase activation increases phosphorylation of glycogen synthase kinase 3beta and thereby reduces cAMP-responsive element transcriptional activity and phosphoenolpyruvate carboxykinase C gene expression in the liver.

Authors:  Nanao Horike; Hideyuki Sakoda; Akifumi Kushiyama; Hiraku Ono; Midori Fujishiro; Hideaki Kamata; Koichi Nishiyama; Yasunobu Uchijima; Yukiko Kurihara; Hiroki Kurihara; Tomoichiro Asano
Journal:  J Biol Chem       Date:  2008-09-17       Impact factor: 5.157

4.  Repression of glucocorticoid-stimulated angiopoietin-like 4 gene transcription by insulin.

Authors:  Taiyi Kuo; Tzu-Chieh Chen; Stephanie Yan; Fritz Foo; Cecilia Ching; Allison McQueen; Jen-Chywan Wang
Journal:  J Lipid Res       Date:  2014-02-24       Impact factor: 5.922

5.  Improving glucose metabolism with resveratrol in a swine model of metabolic syndrome through alteration of signaling pathways in the liver and skeletal muscle.

Authors:  Thomas A Burgess; Michael P Robich; Louis M Chu; Cesario Bianchi; Frank W Sellke
Journal:  Arch Surg       Date:  2011-05

6.  Disrupting the CH1 domain structure in the acetyltransferases CBP and p300 results in lean mice with increased metabolic control.

Authors:  David C Bedford; Lawryn H Kasper; Ruoning Wang; Yunchao Chang; Douglas R Green; Paul K Brindle
Journal:  Cell Metab       Date:  2011-08-03       Impact factor: 27.287

7.  Dynamic Acetylation of Phosphoenolpyruvate Carboxykinase Toggles Enzyme Activity between Gluconeogenic and Anaplerotic Reactions.

Authors:  Pedro Latorre-Muro; Josue Baeza; Eric A Armstrong; Ramón Hurtado-Guerrero; Francisco Corzana; Lindsay E Wu; David A Sinclair; Pascual López-Buesa; José A Carrodeguas; John M Denu
Journal:  Mol Cell       Date:  2018-09-06       Impact factor: 17.970

8.  Glycogen synthase kinase 3 inhibition improves insulin-stimulated glucose metabolism but not hypertension in high-fat-fed C57BL/6J mice.

Authors:  R Rao; C-M Hao; R Redha; D H Wasserman; O P McGuinness; M D Breyer
Journal:  Diabetologia       Date:  2006-12-07       Impact factor: 10.122

9.  Mutation of the PDK1 PH domain inhibits protein kinase B/Akt, leading to small size and insulin resistance.

Authors:  Jose R Bayascas; Stephan Wullschleger; Kei Sakamoto; Juan M García-Martínez; Carol Clacher; David Komander; Daan M F van Aalten; Krishna M Boini; Florian Lang; Christopher Lipina; Lisa Logie; Calum Sutherland; John A Chudek; Janna A van Diepen; Peter J Voshol; John M Lucocq; Dario R Alessi
Journal:  Mol Cell Biol       Date:  2008-03-17       Impact factor: 4.272

Review 10.  Glycogen synthase kinase 3: more than a namesake.

Authors:  Geetha Vani Rayasam; Vamshi Krishna Tulasi; Reena Sodhi; Joseph Alex Davis; Abhijit Ray
Journal:  Br J Pharmacol       Date:  2009-03-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.